Skip to main content

Advertisement

SpringerLink
Log in

On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer

  • Editorial Commentary
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hindié E, Mellière D, Lange F, Hallaj I, de Labriolle-Vaylet C, Jeanguillaume C, et al. Functioning pulmonary metastases of thyroid cancer: does radioiodine influence the prognosis? Eur J Nucl Med Mol Imaging 2003;30:974–81.

    Article  PubMed  Google Scholar 

  2. Hindié E, Zanotti-Fregonara P, Keller I, Duron F, Devaux JY, Calzada-Nocaudie M, et al. Bone metastases of differentiated thyroid cancer: impact of early 131I-based detection on outcome. Endocr Relat Cancer 2007;14:799–807.

    Article  PubMed  Google Scholar 

  3. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892–9.

    Article  CAS  PubMed  Google Scholar 

  4. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005;12:49–64.

    Article  CAS  PubMed  Google Scholar 

  5. Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, et al. Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: (124)I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging 2010. doi:10.1007/s00259-010-1565-3.

  6. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, et al. Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 2010;20:257–63.

    Article  CAS  PubMed  Google Scholar 

  7. Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 2006;65:519–23.

    Article  Google Scholar 

  8. Driedger AA, Kotowycz N. Two cases of thyroid carcinoma that were not stimulated by recombinant human thyrotropin. J Clin Endocrinol Metab 2004;89:585–90.

    Article  CAS  PubMed  Google Scholar 

  9. Taïeb D, Jacob T, Zotian E, Mundler O. Lack of efficacy of recombinant human thyrotropin versus thyroid hormone withdrawal for radioiodine therapy imaging in a patient with differentiated thyroid carcinoma lung metastases. Thyroid 2004;14:465–7.

    Article  PubMed  Google Scholar 

  10. Hung GU, Ho M, Kao CH. Faster radioiodine washout in the treatment of pulmonary metastases of papillary thyroid cancer prepared with recombinant human thyroid-stimulating hormone. Clin Nucl Med 2009;34:316–17.

    Article  PubMed  Google Scholar 

  11. Lazar V, Bidart JM, Caillou B, Mahé C, Lacroix L, Filetti S, et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. J Clin Endocrinol Metab 1999;84:3228–34.

    Article  CAS  PubMed  Google Scholar 

  12. Smith VE, Read ML, Turnell AS, Watkins RJ, Watkinson JC, Lewy GD, et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer. J Cell Sci 2009;122:3393–402.

    Article  CAS  PubMed  Google Scholar 

  13. Barbaro D, Verburg FA, Luster M, Reiners C, Rubello D. ALARA in rhTSH-stimulated post-surgical thyroid remnant ablation: what is the lowest reasonably achievable activity? Eur J Nucl Med Mol Imaging 2010;37:1251–4.

    Article  PubMed  Google Scholar 

  14. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19:1167–214.

    Article  PubMed  Google Scholar 

  15. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154:787–803.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Médecine Nucléaire, Hôpital Saint Antoine, Assistance Publique-Hôpitaux de Paris, 184 Rue du Fbg St. Antoine, 75571, Paris Cedex 12, France

    Paolo Zanotti-Fregonara

  2. Médecine Nucléaire, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris, Paris, France

    Elif Hindié

Authors
  1. Paolo Zanotti-Fregonara
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elif Hindié
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paolo Zanotti-Fregonara.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Zanotti-Fregonara, P., Hindié, E. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 37, 2264–2266 (2010). https://doi.org/10.1007/s00259-010-1608-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-010-1608-9

Keywords

Search

Navigation